J&J Takes Innovative, If Pricey, Route To Ending Hip Suits
Law360, New York (November 21, 2013, 8:31 PM EST) -- In Tuesday's hip implant deal, Johnson & Johnson took the unusual step of accepting responsibility for most of the plaintiffs' insurance liens for surgery costs, a promise that jacks up — perhaps substantially— its $2.5 billion tab, but removes an obstacle to resolution that has increasingly stymied defendants in mass tort litigation.
The company declares in an overview of the agreement that it "will be responsible for most health care insurance liens for medical costs that are directly associated with the revision surgery" of the estimated 8,000 ASR hip implant recipients included in the deal.
Johnson & Johnson's assumption of the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!